Picture: Aurobac

AMR joint venture Aurobac appoints CEO

Aurobac Therapeutics has appointed Florence Séjourné as CEO. The French company is a joint venture, founded by Boehringer Ingelheim, Evotec and bioMérieux and focuses on combating antimicrobial resistance (AMR).

The recently established joint venture, Aurobac Therapeutics SAS, based in Lyon, announced in October the appointment of Florence Séjourné as Chief Executive Officer. She has over 25 years of experience in biotechnology, most recently in leadership positions in antimicrobial resistance (AMR). Séjourné is a founder and board member of the BEAM Alliance, an association representing European biotech companies developing new solutions to combat AMR. She has also spent the last eight years actively advocating for policies that are compatible with small and medium-sized enterprise (SME) biopharmaceuticals to foster much-needed innovation in AMR. Before joining Aurobac, Séjourné was CEO for Da Volterra. Prior to that, she was co-founder and CBO/COO of Genfit (GNFT), a biotech company focused on metabolic and liver diseases.

Séjourné holds degrees in engineering and pharmaceutical sciences from MINES ParisTech and the University of Illinois at Chicago.

Aurobac Therapeutics is a biotech company, founded as a joint venture by biopharmaceutical company Boehringer Ingelheim, life science company Evotec SE and bioMérieux, a specialist in in vitro diagnostics. The 40 million EUR joint venture is financed by Boehringer Ingelheim as the main investor with 30 million euros and by Evotec and bioMérieux with 5 million EUR each and is based in Lyon (France).